Literature DB >> 15694401

Crosstalk between cancer cells and bone microenvironment in bone metastasis.

Toshiyuki Yoneda1, Toru Hiraga.   

Abstract

Bone, as well as lung and liver, is one of the most preferential metastatic target sites for cancers including breast, prostate, and lung cancers. Although the precise molecular mechanisms underlying this preference need to be elucidated, it appears that bone microenvironments possess unique biological features that enable circulating cancer cells to home, survive and proliferate, and destroy bone. In conjunction, cancers that develop bone metastases likely have the capacity to utilize these unique bone environments for colonization and bone destruction. This crosstalk between metastatic cancer cells and bone is critical to the development and progression of bone metastases. Disruption of this interaction will allow us to design mechanism-based effective and specific therapeutic interventions for bone metastases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694401     DOI: 10.1016/j.bbrc.2004.11.070

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  103 in total

1.  Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases.

Authors:  Toru Hiraga; Akira Myoui; Nobuyuki Hashimoto; Akira Sasaki; Kenji Hata; Yoshihiro Morita; Hideki Yoshikawa; Clifford J Rosen; Gregory R Mundy; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

2.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

Review 3.  Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2010-12-03       Impact factor: 5.992

4.  Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.

Authors:  Daichi Fujimoto; Hiroyuki Ueda; Ryoko Shimizu; Ryoji Kato; Takehiro Otoshi; Takahisa Kawamura; Koji Tamai; Yumi Shibata; Takeshi Matsumoto; Kazuma Nagata; Kyoko Otsuka; Atsushi Nakagawa; Kojiro Otsuka; Nobuyuki Katakami; Keisuke Tomii
Journal:  Clin Exp Metastasis       Date:  2014-03-30       Impact factor: 5.150

Review 5.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 6.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

7.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

8.  The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.

Authors:  Brigitte Strahm; Adam D Durbin; Elizabeth Sexsmith; David Malkin
Journal:  Clin Exp Metastasis       Date:  2007-09-01       Impact factor: 5.150

Review 9.  Translational and basic science opportunities in palliative care and radiation oncology.

Authors:  Mai Anh Huynh; Alexander Spektor
Journal:  Ann Palliat Med       Date:  2019-07

Review 10.  Skeletal complications of ADT: disease burden and treatment options.

Authors:  Jacques Planas Morin; Juan Morote Robles
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.